select trial semaglutide cardiovascular outcomes without diabetes 2023 of and tirzepatide for patients with type 2 in clinical practice Full SELECT Results Affirm CV
Description
These benefits ease the strain on the heart, reduce artery plaque buildup, and improve fat distribution, making it an excellent choice for managing long-term cardiovascular risks in people with type 2 diabetes or obesity [1]
In new results released last week on type 2 diabetes, with which patients tend to lose less weight with medications, Lilly said the drug lowered A1C blood sugar levels by an average of 1.7% to 2% at 40 weeks and produced average weight loss of up to 17%, or nearly 17kg
Association of Body Mass Index With Lifetime Risk of Cardiovascular Disease and Compression of Morbidity
Alternative weight loss medications If the regulatory uncertainty around compounded tirzepatide concerns you, it is worth knowing about other options in the weight management space
Introduction Retatrutide Is Not an Obesity Drug
Our practice distinguishes itself by providing a comprehensive ecosystem of care
